This paper is the first to report the benefits of CO 2 laser treatment for pain control in severe oral chronic graftversus-host disease (GVHD). A CO 2 laser device was used during 17 treatment sessions in four patients. The CO 2 laser was applied over the mucosal lesions using 1 W for 2-3 s/1 mm 2 . This treatment resulted in a consistent and significant decrease in pain, measured using a standard visual analogue scale. These results suggest that the CO 2 laser can be used for the alleviation of pain in oral chronic GVHD.
1
Sites commonly involved include the buccal mucosa as well as the lateral and ventral aspects of the tongue. Mucosal lesions can cause significant pain and increase the risk of oral infection. Sclerodermatous changes can cause perioral fibrosis restricting opening and interfering with oral function. 1, 2 The treatment for GVHD usually involved first and second lines of treatments with systemic steroids, cyclosporine and azathioprine. However, oral GVHD is often refractory to systemic treatment, necessitating complementary topical treatment. Furthermore, when the oral mucosa is the solitary site of GVHD involvement, a topical approach may prevent the severe side effects associated with systemic treatments. There are several agents currently used topically for oral GVHD. These include palliative rinses, topical immunosuppressive agents (such as steroids, cyclosporine and azathioprine 1, 3, 4 ) and phototherapy. 5 Adjunctive treatments include oral hygiene to avert infection and measures to prevent complications of xerostomia (such as topical fluorides, saliva substitutes and sialogogues, that is, pilocarpine).
A low-energy laser was first reported to prevent radiation-induced mucositis in cancer patients. 6 A randomized trial with 30 patients found that the low-energy He/ Ne laser is capable of decreasing the severity and duration of oral mucositis associated with radiation therapy as well as reducing patient reports of oral pain. 6 Two recent pilot studies have shown the palliative effects of low-energy laser therapy for oral mucositis. 7, 8 In these studies, lasers were operated in the milli-Watt range. The CO 2 laser that we selected allows treatments at higher power (1-10 W range).
The potential of the CO 2 laser as a pain relief modality was initially reported in a small group of patients suffering from recurrent aphthous ulcers. 9 The palliative effects of the CO 2 laser have not been assessed for other mucosal lesions. Therefore, we speculated that the CO 2 laser can ease suffering from inflammatory lesions of oral chronic GVHD. The exact mechanism of the analgesic effect of the CO 2 laser is unknown. A possible explanation for this is that the CO 2 -laser-activated c-fibers induce a central somatosensory cortical response. 10 Conflicting evidence suggests that the CO 2 laser induces a spinal inhibitory effect via peripheral nerve stimulation. 11 The purpose of our pilot study was to evaluate the efficacy of the CO 2 laser to relieve severe pain caused by oral chronic GVHD.
Patients and methods
A total of 17 laser treatments were provided to four HSCT patients (two males, two females) with severe painful oral chronic GVHD. All patients were hospitalized due to GVHD. During days prior to laser treatment, systemic analgesics (morphine and methadone) and local anesthetic mouthwashes (lidocain) were administered according to the severity of oral mucosal pain and patient demand.
The laser device used was an Opus20 t (ESCq/Sharplan/ Luxar group, Netanya, Israel), a unique integrated laser system incorporating Er:YAG and CO 2 lasers. The CO 2 laser wavelength in this device is 10.6 mm. After a routine calibration procedure, the Opus20 t was operated using 1 W power with a defocused handpiece for 2-3 s per site in a continuous pulsed manner. At 1 cm distance from the mucosa, the beam diameter was 0.67 mm. The treated mucosa was kept wet during the entire procedure.
All patients were examined in the Hospital Oral Medicine department before laser therapy. They were requested to grade their oral pain on a 10-grade scale (visual analogue scale (VAS) -while '0' represents no pain, '10' is regarded as the most severe pain possible). Protective measures during laser operation were taken, including protective eyeglasses, care to avoid burning and fire hazards and an appropriate smoke evacuation system. The rooms in which the laser treatments were carried out complied with safety regulations. The CO 2 laser was applied over the mucosal lesions with an operating distance of less than 5 mm. Post operative VAS was obtained by the same examiner as the pre operative VAS immediately after laser treatment. A detailed description of the treated site was recorded. The patient's need for local anesthesia during the CO 2 treatment and systemic analgesics following treatment was documented as an indication of the level of pain or possible adverse reactions to the CO 2 laser treatment. Albumin levels were compared before and several days following treatment and served as an indication of improved nutrition.
Results
The mean age of the four patients was 30.5 years (range 17-46 years). All patients were hospitalized due to deterioration of extensive GVHD, involving the liver, skin and gastrointestinal tract mucosa. A summary of patient characteristics is shown in Table 1 .
Following laser treatment as described above, there were no visual effects of damage to the oral mucosa, such as coagulation, vaporization or mild erythema.
Sites and treatment outcome are presented in Table 2 . In 14 out of 17 laser treatments, the patients reported immediate post operative relief (82.3%). The VAS values are presented in Table 2 . The improvement in VAS immediately post operatively was 40% (a reduction of the VAS score from 8.09 before the treatment to 4.88 immediately after the treatment). The improvement in the VAS score was reported rapidly, not more than 2 min after CO 2 laser treatment. The average VAS score during CO 2 treatment was 3.47, indicating that the laser emission elicited only a minor nociceptive reaction in the oral mucosa. The treatment was consistently successful in all patients (Table 3) . No aggravation of oral lesions was noted after laser treatment. None of the patients asked for local anesthesia during laser treatment and there were no requests for analgesics following treatment. In two patients, blood albumin levels returned to the normal range within 12 days of the laser treatment (from 34 to 37 and 29 to 38 g/l). Due to the improved albumin levels (a measure of nutritional status), in one patient total parenteral nutrition CO2 laser in oral GVHD S Elad et al was discontinued. The albumin levels remained in the normal range in the other patients (37 and 36 g/l).
Discussion
The CO 2 gas laser emits infrared radiation at a wavelength of 10.6 mm. At this wavelength, water absorption and, therefore, soft-tissue absorption is extremely high. The CO 2 laser is the most effective laser for soft-tissue incisions, excisions and vaporization. Thus, the CO 2 laser was accepted rapidly for surgical procedures. 12 In contrast to low-intensity lasers, to date, the analgesic effect of the CO 2 laser has been reported in one case series for the palliation of aphthae. 9 Our pilot study presents the success of CO 2 laser application for pain control in oral GVHD. In our study, an improvement in technique was extrapolated by the lack of requests for local anesthesia during treatment.
There is little data available on the two major aspects of the management of mucosal lesions with the CO 2 laser.
(1) Healing of mucosal lesions has been reported by Loh et al. 13 In total, 10 patients with lichen planus were treated with a CO 2 laser at a power output of 5 W under local anesthesia. Although this paper concluded that the CO 2 laser contributed to the clinical improvement of the oral lichen planus, the recurrence rate during the 3-year followup period was unclear. In addition to removing the mucosal lichenoid lesion, Loh et al noticed a side effect of an immediate relief of the associated burning sensations and an increased tolerance to hot and spicy foods in all patients. This symptomatic improvement lasted throughout the follow-up period. (2) Pain relief using the CO 2 laser has been reported by Colvard et al. 9 In all, 18 patients with 25 separate minor RAU were treated. Their treatment protocol included pre-operative pain medication, local anesthesia, radiation of each lesion with 4 W of CO 2 -generated photon energy and, if necessary, post-operative analgesics. During treatment with the laser, as much necrotic tissue as possible was removed. In all, 88.8% of patients in Colvard's study were completely pain free following anesthetic resolution, and none of the patients required post-operative medication for pain relief. The healing process was with minimal edema. Colvard et al were the first to recognize the potential use of the CO 2 laser in providing pain alleviation for RAU.
In our case series, a defocused beam of a CO 2 laser at minimal power (1 W) was used for mucosal pain relief. The lower laser emission output enabled treatment without local anesthesia. Pain relief was noted when analyzed both on a per treatment session basis and on a per patient basis. No effect on oral mucosal tissues, such as coagulation or vaporization, was visible. The treatment led to an improved nutritional status, indicated by the blood albumin levels and by the termination of total parenteral nutrition needs in one patient. Improved nutrition reflecting better oral functioning was noted following CO 2 laser treatment. This improvement was coincident with a decreased intake of systemic analgesics, emphasizing the local effects of the laser treatment.
Our ability to compare the responses per anatomical site is limited because of the small number of patients in the study. The overall impression from the VAS scores is of a favorable effect, with less improvement following treatment of the tongue.
Although our present study group was small and the follow-up period was limited, our findings have important implications with respect to sparing potential side effects of systemic analgesic medication. In patients with a high morbidity and mortality, such as in this group, any treatment added to the supportive repertoire is significant.
Most of the patients enrolled in this study were immunocompromised. The CO 2 laser allows control of the lesions with limited tissue penetration, thus minimizing damage to underlying tissues. Additional benefits of the laser include the presumed reduction of bacterial load and coagulation of bleeding areas. 14, 15 Caution must be exercised when using the CO 2 laser, and strict parameters were adhered to in the present study. High-power CO 2 laser can cause mucosal damage, in a manner similar to the classic effects of CO 2 lasers, namely incision, excision and vaporization of tissues. All these effects should be avoided when using the device for an analgesic effect.
The underlying mechanism of the analgesic effect of the CO 2 laser is as yet unknown. It was speculated to be the result of microcoagulation or sealing of nerve endings. 16 This theory contradicts a recent study showing that the number of intact peripheral nerve structures in laser-treated sites were similar to the numbers in cautery-and scalpeltreated sites. 17 Another possible explanation is based on the findings that the activation of peripheral inhibitory nerves decreases neural signals from the spine to the cortex (gate theory). 11 In contrast, Tran et al 10 documented a central somatosensory cortical effect of peripheral dermal stimulation with the CO 2 laser. These neural mechanisms are supported by the rapid improvement in sensory perception after the CO 2 laser treatment in our study. An interesting explanation for the analgesic effect of low-intensity diode laser, based on clinical 18 and laboratory 19 studies, showed an alteration in prostaglandin levels, consequently increasing the anti-inflammatory effect. However, the CO 2 lasertissue interaction may not be the same as the low-intensity laser.
In this study, a new indication is suggested for a CO 2 laser in symptomatic treatment of mucosal lesions. The elevated analgesic response rate to a high-intensity laser, without local anesthesia, indicates a promising treatment modality. More research is warranted to confirm the analgesic effects of the CO 2 laser in large-scale studies to investigate the biologic mechanisms and significance of this No. ¼ number; VAS ¼ visual analogue scale.
CO2 laser in oral GVHD S Elad et al analgesic effect and to determine the indications for laser therapy in oral medicine.
